Kymera Therapeutics (KYMR) Revenue (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Revenue data on file, last reported at $34.4 million in Q1 2026.

• Revenue for Q1 2026 came in at $34.4 million, up 55.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.5 million (down 12.58% YoY), and the FY2025 annual result was $39.2 million, down 16.7% from the prior year.
• Revenue grew to $34.4 million in Q1 2026 per KYMR's latest filing, from $2.9 million in the prior quarter.
• Over five years, Revenue peaked at $47.9 million in Q4 2023 and troughed at $2.8 million in Q3 2025.
• A 5-year average of $14.5 million and a median of $10.3 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2024: Revenue soared 196.7% in 2023, then sank 84.56% in 2024.
• A 5-year view of Revenue shows it stood at $16.1 million in 2022, then surged by 196.7% to $47.9 million in 2023, then slumped by 84.56% to $7.4 million in 2024, then sank by 61.18% to $2.9 million in 2025, then surged by 1097.39% to $34.4 million in 2026.
• Business Quant data shows KYMR's Revenue at $34.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.8 million in Q3 2025.